Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study
Authors' conclusion
In this nationwide propensity-score matched cohort study involving individuals with diabetes and TG ≥ 150 mg/dL, the risk of all-cause death and ASCVD was significantly lower with fenofibrate use in conjunction with statin treatment compared to statin treatment alone. However, this finding was significant only in individuals with relatively high LDL-C levels.
Study context
- Population
- Individuals with diabetes, triglyceride (TG) ≥ 150 mg/dL, no prior atherosclerotic cardiovascular disease (ASCVD), using statins; National Health Information Database, Republic of Korea, 2010–20171:1 matched cohort
- Exposure
- Fenofibrate plus statin vs statin alone
- Fenofibraten = 110,723
- Outcome
- Newly diagnosed myocardial infarction (MI), stroke, MI and/or stroke, and all-cause mortality
- Follow-up
- mean 4.03-year follow-up
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
MI; stroke; MI and/or stroke; all-cause death
Each group vs controlEstimate (95% CI)
Fenofibrate
HR (MI) 0.878(0.827–0.933)
Fenofibrate
HR (stroke) 0.901(0.848–0.957)
Fenofibrate
HR (MI and/or stroke) 0.897(0.858–0.937)
Fenofibrate
HR (all-cause death) 0.716(0.685–0.749)
Observational data: associations, not effects.
Further findings
- Beneficial effects consistent in subgroup with TG 150-199 mg/dL but differed according to low-density lipoprotein cholesterol (LDL-C) levels
Original publication
Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study. Cardiovasc Diabetol. Published 18 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →